The FDA has approved Lebrikizumab for clinical trials in safety and efficacy, a second biologic for patients over 18 with moderate-to-severe eczema. 75% of patients improved their Eczema Area Severity Index (EASI) from baseline to week 16. Read article here
With last year's news of eczema being an inflammatory condition, like psoriasis, and treatable through the immune system the first biologic for eczema, Dupixent was approved. Click here ~ Dr. Emma Guttman-Yassky, MD, PhD speech at the American Academy of Dermatology event with Eczema discovery.
Learn more about our ~ Psoriasis and Eczema Biologic Program